Adherence and quality of life in women with breast cancer being treated with oral hormone therapy

This publication has 26 references indexed in Scilit:

• Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women
  Clinical Breast Cancer, 2018
• Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial
  The Lancet, 2014
• Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
  Breast Cancer Research and Treatment, 2012
• Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
  Breast Cancer Research and Treatment, 2012
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
  The Lancet, 2011
• Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
  Breast Cancer Research and Treatment, 2010
• Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
  The Lancet, 2005
• An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane
  Cancer, 2002
• Tamoxifen in the Treatment of Breast Cancer
  New England Journal of Medicine, 1998
• The Development of the World Health Organization Quality of Life Assessment Instrument (the WHOQOL)
  1994